Clinical Trial Update: Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating Emavusertib (CA-4948) in combination with FOLFOX chemotherapy plus Bevacizumab for metastatic colorectal cancer (includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Unresectable Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Emavusertib (CA-4948) (emavusertib)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Status: RECRUITING